



Title	Nitric oxide stimulates IP3 production via a cGMP/ PKG-dependent pathway in rat pancreatic acinar cells
Author(s)	Moustafa, Amira; Sakamoto, Kentaro Q; Habara, Yoshiaki
Citation	Japanese Journal of Veterinary Research, 59(1), 5-14
Issue Date	2011-02
DOI	10.14943/jjvr.59.1.5
Doc URL	<a href="http://hdl.handle.net/2115/44860">http://hdl.handle.net/2115/44860</a>
Type	bulletin (article)
File Information	JJVR59_1p005-014.pdf



[Instructions for use](#)

# Nitric oxide stimulates IP<sub>3</sub> production via a cGMP/PKG-dependent pathway in rat pancreatic acinar cells

Amira Moustafa<sup>1, 2)</sup>, Kentaro Q. Sakamoto<sup>1)</sup> and Yoshiaki Habara<sup>1,\*)</sup>

<sup>1)</sup>Laboratory of Physiology, Department of Biomedical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo 060-0818, Japan.

<sup>2)</sup>Department of Physiology, Faculty of Veterinary Medicine, Zagazig University, Zagazig 44519, Egypt.

Received for publication, November 1, 2010; accepted, November 25, 2010

## Abstract

In an attempt to explore the functioning of nitric oxide (NO) in pancreatic exocrine cells, we have recently obtained several lines of circumstantial evidence indicating that one of molecular targets of NO is phospholipase C (PLC), the activation of which leads to an increase in the cytosolic Ca<sup>2+</sup> concentration ([Ca<sup>2+</sup>]<sub>i</sub>) via inositol 1, 4, 5-trisphosphate, IP<sub>3</sub>. However, whether IP<sub>3</sub> is actually produced by NO has not yet been substantiated. The present study was therefore designed to directly measure the intracellular IP<sub>3</sub> concentration ([IP<sub>3</sub>]<sub>i</sub>) for better understanding of the underlying mechanisms with the help of pharmacological tools. [IP<sub>3</sub>]<sub>i</sub> was measured using a fluorescence polarization technique (HitHunter™). We obtained the following results: 1) varying concentrations of an NO donor, sodium nitroprusside (SNP), elevated [IP<sub>3</sub>]<sub>i</sub>, 2) this elevation was completely inhibited in the presence of the soluble guanylyl cyclase (sGC) inhibitor, 1H-[1, 2, 4] oxadiazolo [4, 3-a] quinoxalin-1-one (ODQ), 3) varying concentrations of the cGMP analogue, 8-Br-cGMP, also increased [IP<sub>3</sub>]<sub>i</sub>, 4) the cGMP analogue-induced IP<sub>3</sub> production was abolished by pretreatment with either a PLC inhibitor, U73122, or a G-protein inhibitor, GP2A, and 5) KT5823, a potent and highly selective inhibitor of cGMP-dependent protein kinase G (PKG), also abolished the IP<sub>3</sub> production induced by 8-Br-cGMP. These results suggest that the NO-induced [Ca<sup>2+</sup>]<sub>i</sub> increase is triggered by an increase in [IP<sub>3</sub>]<sub>i</sub> located downstream from intracellular cGMP elevation. In this intracellular pathway, each sGC, cGMP-dependent PKG, G-protein and PLC were suggested to be involved. The present work provides new insights into the intracellular signaling accelerated by NO. NO triggers a [Ca<sup>2+</sup>]<sub>i</sub> increase via cGMP and IP<sub>3</sub> in pancreatic acinar cells.

Key words: Ca<sup>2+</sup>, cGMP, IP<sub>3</sub>, nitric oxide, pancreatic acini

\*Corresponding author: Yoshiaki Habara, Laboratory of Physiology, Department of Biomedical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo 060-0818, Japan  
Phone: +81-11-706-5199. Fax: +81-11-706-5202. E-mail: habara@vetmed.hokudai.ac.jp

## Introduction

Nitric oxide (NO) plays critical roles in various biological systems. This bioactive gas is formed from an amino acid, L-arginine, via a reaction catalyzed by NO synthases (NOSs) that are either constitutive or inducible<sup>20)</sup> in the presence of molecular oxygen. Physiologically diverse effects exerted by this gaseous radical are regarded to be intermediated largely by soluble guanylyl cyclase (sGC), which is considered to be a receptor for NO. Cyclic GMP produced by catalytic action of sGC activates cGMP-dependent protein kinase G (PKG) to phosphorylate an array of proteins<sup>22)</sup>.

G-protein-mediated intracellular Ca<sup>2+</sup> signaling has long been depicted as a key event that initiates exocrine secretion in pancreatic acini. The signaling commences from binding of G-protein-coupled receptors with a variety of agonists followed by activation of phospholipase C (PLC), which promotes elevation of the intracellular IP<sub>3</sub> concentration ([IP<sub>3</sub>]<sub>i</sub>) in such a way that this phosphoinositide metabolite triggers the release of Ca<sup>2+</sup> from intracellular stores<sup>35)</sup>. Lines of evidence have demonstrated that NO could induce Ca<sup>2+</sup> release in several cell types<sup>3,26)</sup> either via PKG-coupled activation of ADP-ribosyl cyclase, resulting in increased synthesis of a potent Ca<sup>2+</sup> mobilizing agent, cyclic ADP-ribose<sup>3,36)</sup>, or via direct nitrosylation of regulatory thiol groups of ryanodine receptors<sup>30)</sup>. Thus, in some cells, Ca<sup>2+</sup> and NO appear to work synergistically in the regulation of cellular homeostasis. However, some controversial findings have also been reported regarding the effect of cGMP on the intracellular Ca<sup>2+</sup> concentration ([Ca<sup>2+</sup>]<sub>i</sub>) depending on the type of cell. Elevation of [Ca<sup>2+</sup>]<sub>i</sub> has been described in hepatocytes<sup>28)</sup> and sea urchin eggs<sup>9,11)</sup> and suppression of [Ca<sup>2+</sup>]<sub>i</sub> was noted in cardiac myocytes<sup>19)</sup>, cerebellar neurons<sup>8)</sup> and vascular smooth muscle cells<sup>5)</sup>. The idea that phosphorylation of the IP<sub>3</sub> receptor by PKG potentiates IP<sub>3</sub>-dependent Ca<sup>2+</sup> release was proposed for hepatocytes<sup>28)</sup>, whereas it was

hypothesized that phosphorylation of ADP-ribosyl cyclase stimulates the synthesis of cyclic ADP-ribose, which potentiates Ca<sup>2+</sup>-induced Ca<sup>2+</sup> release from ryanodine-sensitive stores in sea urchin eggs<sup>9)</sup>. For G-protein-coupled receptors, negative modulation by cGMP has been shown. Decreased generation of the two major second messengers, IP<sub>3</sub> and diacylglycerol, and blunting of Ca<sup>2+</sup> release from intracellular stores were demonstrated<sup>18)</sup>. In these receptors, the site of modulation was presumed to be at the G-protein/PLC interface<sup>26)</sup>.

NO is well known to have a functional inhibitory role on IP<sub>3</sub> production in anterior pituitary cells<sup>33)</sup>, megakaryocytes<sup>31)</sup> and ciliary and iris sphincter smooth muscle cells<sup>6)</sup>. In the pancreatic exocrine gland, where it is known that NOSs exist, however, the functional role of NO in the machinery of exocrine secretion, especially in terms of [IP<sub>3</sub>]<sub>i</sub>, is unclear. Recent studies in our laboratory suggested that NO could mobilize Ca<sup>2+</sup> from IP<sub>3</sub>-sensitive stores via cGMP and/or a PLC pathway in pancreatic acinar cells<sup>21)</sup> but its detailed cascade is not known. Accordingly, the present work was designed to further explore the NO-related signaling pathway by especially focusing on actual changes in [IP<sub>3</sub>]<sub>i</sub> and to obtain insights into the overall signaling pathway accelerated by NO mediating [Ca<sup>2+</sup>]<sub>i</sub> dynamics in pancreatic acinar cells.

## Materials and Methods

*Chemicals:* Chromatographically purified collagenase (CLSPA) was purchased from Worthington Biochemical (Lakewood, NJ, USA). U-73122, dimethyl sulfoxide (DMSO), bovine serum albumin (BSA), Dulbecco's phosphate-buffered saline containing neither CaCl<sub>2</sub> nor MgCl<sub>2</sub> (PBS), soybean trypsin inhibitor (type1-S) and the cGMP analogue, 8-Br-cGMP, were from Sigma (St. Louis, MO, USA). HEPES was from Dojindo (Kumamoto, Japan). Eagle's essential amino acid (MEM) without L-glutamine was

purchased from Invitrogen (Carlsbad, CA, USA). Sodium nitroprusside (SNP) and 1H-[1, 2, 4] oxadiazolo [4, 3-a] quinoxalin-1-one (ODQ) were obtained from Wako Pure Chemicals (Osaka, Japan). A  $G_q$ -protein antagonist peptide, GP2A<sup>27</sup>, and a PKG inhibitor, KT5823, were purchased from Calbiochem (La Jolla, CA, USA).

*Solutions:* Normal Ringer's solution used for acinar isolation (Standard HEPES-buffered solution) contained (mM): NaCl, 138.0; KCl, 4.7; CaCl<sub>2</sub>, 1.3; MgCl<sub>2</sub>, 1.13; Na<sub>2</sub>HPO<sub>4</sub>, 1.0; D-glucose, 5.5; HEPES, 10.0 supplemented with MEM plus 2 mM L-glutamine, 1 mg/ml BSA and 0.1 mg/ml soybean trypsin inhibitor. The pH was adjusted to 7.4 with NaOH.

*Isolation of pancreatic acini:* All experiments conformed to the guidelines on the ethical use of animals set by the U.S. National Institutes of Health and were approved by the Institutional Animal Care and Use Committee of the Graduate School of Veterinary Medicine, Hokkaido University. All efforts were made to minimize animal suffering and to reduce the number of animals used. Adult specific pathogen-free male Wistar rats weighing 200–250 g purchased from Clea Japan (Tokyo, Japan) were used throughout the experiments. The animals were fasted overnight with free access to water and maintained at 22°C in an air-controlled room with a 12:12-h light-dark cycle. The animals were anesthetized by CO<sub>2</sub> inhalation and euthanized by exsanguination. The pancreata were removed quickly and freed from fat and lymph nodes. The pancreatic acini were obtained by collagenase digestion according to a method reported previously<sup>21</sup>. Briefly, 5 ml of standard solution containing 60–75 U/ml collagenase was injected into the interstitium of the pancreatic tissue and digested in a conical flask at 37°C under vigorous shaking for a total of 60 min. After 30 min of digestion, old collagenase in the flask was replaced with 5 ml of new collagenase. Mechanical disruption of the tissue was

performed by gentle suction through pipettes with decreasing orificial size. The acinar suspension was then filtrated through 150 µm nylon mesh, rinsed at least twice with PBS, pelleted (x60 g) and resuspended in a suitable amount of PBS. Acinar cell viability was virtually 100% when assessed by the trypan blue exclusion test.

*Measurement of [IP<sub>3</sub>]<sub>i</sub>:* The amount of IP<sub>3</sub> was measured using HitHunter™ IP<sub>3</sub> Fluorescence Polarization Assay Kits (DiscoverX Tech, Fremont, CA, USA), a reliable and convenient methodology based on competitive binding between an IP<sub>3</sub> fluorescence tracer and unlabeled IP<sub>3</sub> from the cell lysates or standards. Free IP<sub>3</sub> competes at the IP<sub>3</sub> binding protein and allows the IP<sub>3</sub> tracer to rotate freely upon excitation with plane polarized light. The polarized signal is inversely proportional to the amount of the free unlabelled IP<sub>3</sub>; thus, as the concentration of IP<sub>3</sub> is increased the polarization signal is decreased<sup>25</sup>. Black 384-well plates (Greiner Bio-One, Frickenhausen, Germany) were used for measurement of IP<sub>3</sub>. Briefly, cells were treated with different agonists (SNP or 8-Br-cGMP) for designated periods in the presence or the absence of various inhibitors. The cellular reaction was terminated by placing cells on ice followed by addition of 0.2 N perchloric acid to lyse the cells. The plate was then shaken at 650 rpm for 5 min. The IP<sub>3</sub> tracer was subsequently added to each well and the IP<sub>3</sub> binding protein was finally added to the plate. The polarized fluorescence from the IP<sub>3</sub> tracer (fluorescein) was read using a Synergy™ 4 Multi-Mode Microplate Reader (BioTek Instruments, Winooski, VT) with a polarization mirror, and 485 nm excitation filter and 530 nm emission filter. The [IP<sub>3</sub>]<sub>i</sub> was calculated from the IP<sub>3</sub> standard curve, which was prepared from 3-fold serial dilutions of IP<sub>3</sub> standards ranging from  $1.33 \times 10^{-6}$  to  $6.7 \times 10^{-11}$  M and fitted with a four-parameter Hill equation.

*Statistical analysis:* Data obtained from triplicate assays were collected from at least three independent experiments. The [IP<sub>3</sub>]<sub>i</sub> was expressed as the percent of prestimulated basal [IP<sub>3</sub>]<sub>i</sub> (nM) by setting the basal IP<sub>3</sub> concentration as 100% (baseline). The area under the curve (AUC) was also calculated for the whole time course (300 sec) to assess IP<sub>3</sub> production (% change) and represented as (AUC percent·sec). Data are presented as mean ± SE. The statistical analysis was performed using Student's *t*-test with a value of *P* < 0.05 being considered significant.

## Results


### SNP-induced IP<sub>3</sub> production

Pancreatic acini were stimulated with the NO donor, SNP, and IP<sub>3</sub> production was directly measured. As shown in Fig. 1a, SNP (50 μM) induced a marked increase in [IP<sub>3</sub>]<sub>i</sub> and this increase appeared to be oscillatory with a frequency of approximately one spike per 2 min, which was equivalent to that of NO-induced Ca<sup>2+</sup> oscillation<sup>21</sup>. Different concentrations of SNP from 20 μM to 1 mM also elevated [IP<sub>3</sub>]<sub>i</sub> (Fig. 1b). All concentrations of SNP tested induced almost the same degree of elevation with some decrease at a higher concentration. This finding suggested that NO activated PLC as IP<sub>3</sub> was produced from PLC-mediated hydrolysis of PIP<sub>2</sub>.

### Involvement of sGC/cGMP in NO-induced IP<sub>3</sub> production

Generally, a guanylyl cyclase, especially sGC, is considered to be one of the most essential proteins activated by NO and a consequence of activation of this enzyme is an increase in the intracellular cGMP concentration. We therefore next tried to evaluate the possible involvement of sGC/cGMP in the NO-activated intracellular pathway from the viewpoint of IP<sub>3</sub> production. Two prominent inhibitors were applied. First,

isolated acini were pretreated with ODQ, a potent and selective inhibitor of NO-sensitive guanylyl cyclase (GC). Pretreatment with ODQ at 100 μM for 30 min before and 5 min during SNP application almost completely inhibited the 50 μM SNP-induced [IP<sub>3</sub>]<sub>i</sub> increase as shown in Fig. 2a. The AUC of IP<sub>3</sub> production was found to decrease by 97% in the presence of ODQ (Fig. 2b). This result implied a principal role of GC, mainly sGC, in the pathway of NO-induced IP<sub>3</sub> production. As the downstream product of sGC is cGMP, we next applied 8-Br-cGMP, a membrane-permeable and stable analogue of cGMP, and examined whether, as with the NO donor, IP<sub>3</sub> production could be induced to further




**Fig. 1. SNP-induced IP<sub>3</sub> production.** (a) Time course of IP<sub>3</sub> production induced by 50 μM SNP. Intracellular IP<sub>3</sub> was measured every 30 sec and normalized as % of basal value. (b) Isolated pancreatic acini were stimulated with different concentrations of SNP. The actual IP<sub>3</sub> concentrations in nM were measured every 30 sec for 5 min and converted to % of basal. Then the area under the curve (AUC) was obtained. Each column represents mean ± SE of AUC (n = 3-4). \**P* < 0.05 by Student's *t*-test.

substantiate the potential involvement of sGC. As expected, application of 8-Br-cGMP at varying concentrations ranging from 0.1  $\mu\text{M}$  to 1 mM was also found to induce oscillatory  $[\text{IP}_3]_i$  increases (Fig. 3a–d). The  $\text{IP}_3$  level was increased by 1.7- to 2.4-fold over the basal level. These results indicated that NO stimulated  $\text{IP}_3$  formation via the sGC/cGMP signaling pathway.

#### Stimulation of PLC by cGMP

A general understanding that  $\text{IP}_3$  is formed by catalytic activity of PLC would raise the question of whether the cGMP-induced  $\text{IP}_3$  production found in the foregoing experiments was mediated by PLC. To address this question, acini were pretreated with a PLC inhibitor, U73122, and cGMP-induced  $\text{IP}_3$  production was measured. The  $[\text{IP}_3]_i$  elevation induced by 0.1  $\mu\text{M}$  8-Br-cGMP was significantly inhibited (by 66%)

by the pretreatment of acini with 2  $\mu\text{M}$  U73122 for 30 min when compared with the untreated control value (Fig. 4a, b). This result indicated that cGMP was able to activate PLC and induce subsequent  $\text{IP}_3$  production. The next question is by what mechanism cGMP activates PLC. We focused on G-protein, as PLC is activated by an  $\alpha$ -subunit cleaved from trimeric G-protein. The acini were preincubated with a  $G_q$ -protein antagonist peptide (10  $\mu\text{M}$ ), GP2A, for 30 min before and 5 min during stimulation with 0.1  $\mu\text{M}$  8-Br-cGMP. As depicted in Fig. 4b,  $\text{IP}_3$  production induced by 8-Br-cGMP was markedly diminished in the presence of GP2A, which was also obvious in the time course of 8-Br-cGMP-induced changes in  $[\text{IP}_3]_i$  (Fig. 4a). The  $\text{IP}_3$  production was found to decrease by 72% (Fig. 4b). From these results, we speculated that cGMP most likely stimulated  $\text{IP}_3$  production, not completely but largely, via a well-characterized G-protein/PLC pathway.



**Fig. 2. Effect of ODQ on SNP-induced  $\text{IP}_3$  production.** (a) Time course of  $\text{IP}_3$  production induced by 50  $\mu\text{M}$  SNP in the presence (open circle) and absence (closed circle) of 100  $\mu\text{M}$  ODQ. (b) AUC in the presence and absence of 100  $\mu\text{M}$  ODQ. Values are means  $\pm$  SE ( $n = 3$ ). \* $P < 0.05$ .


#### Effect of KT5823 on cGMP-induced $\text{IP}_3$ production

It is documented that the intracellular action of cGMP is primarily mediated by a cGMP-dependent PKG, but several types of cyclic nucleotide-activated ion channels are also reported to be involved<sup>7,17</sup>. Thus, whether PKG mediated cGMP-induced  $\text{IP}_3$  production was examined by using a highly cell-permeable and selective inhibitor of PKG, KT5823<sup>10,13</sup>. Pretreatment with 10  $\mu\text{M}$  KT5823 for 30 min significantly blocked cGMP-induced  $[\text{IP}_3]_i$  elevation by 86% (Fig. 4b), indicating that the stimulatory effect of the cGMP analogue depended upon activation of PKG to elicit  $\text{IP}_3$  production.

## Discussion

#### NO-induced $\text{IP}_3$ production

NO is an essential intracellular messenger involved in a variety of crucial physiological events. Previous work from our group




**Fig. 3. 8-Br-cGMP-induced IP<sub>3</sub> production.** Typical examples of time courses of IP<sub>3</sub> production induced by 0.1 (a), 10 (b), 100 μM (c) and 1 mM (d) 8-Br-cGMP. IP<sub>3</sub> concentration was measured every 30 sec for 5 min.

demonstrated a novel NO/PLC signaling pathway relaying NO-induced Ca<sup>2+</sup> oscillation and activation of cGMP, PLC, IP<sub>3</sub> and resultant Ca<sup>2+</sup> release from IP<sub>3</sub>-sensitive stores in rat pancreatic acini<sup>21</sup>. Several reports have shown that NO, through PKG activation, modulates phosphoinositide metabolism<sup>4,37</sup>, sensitivity of the IP<sub>3</sub> receptor<sup>13,15</sup> and PLC activation, which results in production of IP<sub>3</sub>, triggering Ca<sup>2+</sup> release from nonmitochondrial intracellular stores<sup>10,14</sup>. However, little is known about the mechanisms of the NO action on inositol phosphate metabolism in pancreatic acinar cells. In this study, we especially focused on actual IP<sub>3</sub> production by NO or cGMP in pancreatic acini to further substantiate our previous assumption.

A stimulatory effect by NO gas on IP<sub>3</sub> formation has been reported only in chromaffin cells<sup>24</sup>. On the other hand, an inhibitory action has been documented in anterior pituitary cells<sup>33</sup>, megakaryocytes<sup>31</sup> and ciliary and iris sphincter smooth muscle cells<sup>6</sup>. For pancreatic

exocrine cells, no reports are available in which the [IP<sub>3</sub>]<sub>i</sub> was directly measured after NO/cGMP stimulation. In the current study, we attempted to actually measure the IP<sub>3</sub> level in isolated rat pancreatic acini in order to examine the effects of NO on IP<sub>3</sub> production and tried to better understand the underlying mechanism of NO-induced Ca<sup>2+</sup> release. First, we found that an NO donor, SNP, induced oscillatory changes in [IP<sub>3</sub>]<sub>i</sub> with a frequency of approximately one spike per two minutes, which appeared to be mostly identical to the frequency of NO-induced Ca<sup>2+</sup> dynamics in pancreatic acinar cells<sup>21</sup>. This would indicate that NO-induced [Ca<sup>2+</sup>]<sub>i</sub> oscillation occurred due to oscillatory changes in [IP<sub>3</sub>]<sub>i</sub>. In other words, this implies a strong correlation between IP<sub>3</sub> and Ca<sup>2+</sup> in the NO effect. Thus, as in chromaffin cells<sup>24</sup> but not in other cells<sup>6,31,33</sup>, an essential action of NO in pancreatic acinar cells would be to stimulate IP<sub>3</sub> production.



**Fig. 4. Effects of U73122, GP2A and KT5823 on 8-Br-cGMP-induced IP<sub>3</sub> production.** (a) Time courses of IP<sub>3</sub> production induced by 0.1 μM 8-Br-cGMP in the absence (●) and presence of 2 μM U73122 (■), 10 μM GP2A (△) and 10 μM KT5823 (▲). (b) AUC of 0.1 μM 8-Br-cGMP-induced IP<sub>3</sub> production in the absence and presence of 2 μM U73122, 10 μM GP2A and 10 μM KT5823. Data are means ± SE (n = 3–4). \*P < 0.05.

#### *sGC and cGMP in NO-induced IP<sub>3</sub> production*

The next question would be whether the cGMP pathway intermediates NO-induced IP<sub>3</sub> production. In many biological systems, it is known that the effects of NO are mediated by cGMP. In the present study, the possible relevance of this cascade was assessed in two ways; first, acini were pretreated with ODQ, a highly selective and irreversible inhibitor of guanylyl cyclase, and we found that SNP-induced IP<sub>3</sub> production was significantly attenuated, indicating that activation of guanylyl cyclase, most likely sGC, by NO is an essential step of the pathway of IP<sub>3</sub> production. Second, instead of SNP, we utilized 8-Br-cGMP to examine if IP<sub>3</sub> production was stimulated by the sGC product, cGMP, and found that this analogue also increased [IP<sub>3</sub>]<sub>i</sub>. This evidence indicated that, in addition to sGC, cGMP production was a subsequent step following sGC activation in

NO-induced IP<sub>3</sub> production and the resultant Ca<sup>2+</sup> response in pancreatic acinar cells. A similar idea was also proposed for parotid acinar cells and chromaffin cells<sup>32,34</sup>.

#### *PLC mediates NO-induced IP<sub>3</sub> production*

The finding of involvement of cGMP in NO-induced IP<sub>3</sub> production then led us to further investigate how cGMP elicits IP<sub>3</sub> production. It has been previously reported that NO might modulate PLC activity through cGMP<sup>4,37</sup>. We tested this possibility by using U73122 and found that the 8-Br-cGMP-induced increase in [IP<sub>3</sub>]<sub>i</sub> was significantly inhibited. To our knowledge this is the first evidence to indicate the activation of PLC by cGMP leading to production of IP<sub>3</sub> in pancreatic acinar cells. A similar pathway was also proposed in parotid acinar cells, in which NO could activate PLC, IP<sub>3</sub> synthesis and Ca<sup>2+</sup> release through cGMP<sup>32</sup>.

### *G-protein is involved in NO-induced IP<sub>3</sub> production*

Our findings indicated that NO triggered a rise in cGMP followed by activation of PLC and subsequent IP<sub>3</sub> production and Ca<sup>2+</sup> release from IP<sub>3</sub>-sensitive stores. It is widely recognized that PLC activation is commenced by binding of the  $\alpha$ -subunit of the trimeric G-protein molecule. If this step also occurs in the process discussed above, 8-Br-cGMP-induced IP<sub>3</sub> production should be inhibited by G-protein inhibitors. In the current study, we utilized the G-protein antagonist peptide, GP2A. Interestingly, as 8-Br-cGMP-induced IP<sub>3</sub> production was totally abolished in the presence of GP2A, we speculated that NO activated G-protein which is downstream of cGMP formation. The G-protein  $\alpha$ -subunit could then bind with PLC, which accelerated IP<sub>3</sub> production and Ca<sup>2+</sup> release.

### *PKG participates in NO-induced IP<sub>3</sub> production*

The effects of cGMP are known to be mediated by multiple factors; one of which is PKG<sup>29</sup>). To investigate the possible involvement of this kinase, we applied a PKG inhibitor, KT5823, to examine its effect on 8-Br-cGMP-induced IP<sub>3</sub> production. The result showed a marked decrease in cGMP-induced IP<sub>3</sub> production in the presence of KT5823, suggesting that a PKG-dependent pathway was involved in cGMP-stimulated IP<sub>3</sub> production.

Considering these results together, we presume that NO activates sGC and elevates the intracellular cGMP level. This cyclic nucleotide then binds with PKG and affects its catalytic potential, which then could phosphorylate PLC as demonstrated by Huang *et al.*<sup>12</sup>) and Xia *et al.*<sup>37</sup>), though the end effect reported by them was not potentiation but inhibition of [Ca<sup>2+</sup>]<sub>i</sub>. Processing of this signaling finally induces IP<sub>3</sub> production and the resultant [Ca<sup>2+</sup>]<sub>i</sub> increase. Unlike other cells<sup>3,30,36</sup>), ADP-ribosylation and/or nitrosylation may be a minor step even if it occurs in pancreatic acinar cells.

In conclusion, the present study is the first

to show that an NO-PKG signaling pathway may be coupled to IP<sub>3</sub> production in pancreatic acinar cells and that this cascade is mediated by cGMP/G-protein/PLC activation, which, we think, is a novel signaling pathway functioning between NO and Ca<sup>2+</sup> mobilization in these cells. This may provide a better understanding of the mechanism of the action of NO in the exocrine pancreas.

### **Acknowledgements**

The authors thank K. Yamaguchi, S. Murakami and T. Tatebe for their technical assistance. A part of this study was financially supported by the Egyptian government (oversea scholarship to A. M.).

### **References**

- 1) Bredt, D. S. and Snyder, S. H. 1992. Nitric oxide, a novel neuronal messenger. *Neuron*, **8**: 3-11.
- 2) Busik, J., Habara, Y., Maruyama, T. and Kanno, T. 1993. Inhibition by a receptor-mediated Ca<sup>2+</sup> entry blocker, SK&F 96365, of Ca<sup>2+</sup> and secretory responses in rat pancreatic acini. *Eur. J. Pharmacol.*, **247**: 273-281.
- 3) Clementi, E., Riccio, M., Sciorati, C., Nisticò, G. and Meldolesi, J. 1996. The type 2 ryanodine receptor of neurosecretory PC12 cells is activated by cyclic ADP-ribose. *J. Biol. Chem.*, **271**: 17739-17745.
- 4) Clementi, E., Sciorati, C., Riccio, M., Miloso, M., Meldolesi, J. and Nisticò, G. 1995. Nitric oxide action on growth factor-elicited signals. *J. Biol. Chem.*, **270**: 22277-22282.
- 5) Cornwell, T. L. and Lincoln, T. M. 1989. Regulation of intracellular Ca<sup>2+</sup> levels in cultured vascular smooth muscle cells. Reduction of Ca<sup>2+</sup> by atriopeptin and 8-bromo-cyclic GMP is mediated by cyclic GMP-dependent protein kinase. *J. Biol. Chem.*, **264**: 1146-1155.
- 6) Ding, K-H. and Abdel-Latif, A. A. 1997. Actions of C-type natriuretic peptide and sodium nitroprusside on carbachol-stimulated inositol phosphate formation and contraction

- in ciliary and iris sphincter smooth muscles. *Invest. Ophthalmol. Vis. Sci.*, **38**: 2629–2638.
- 7) Finn, J. T., Grunwald, M. E. and Yau, K-W. 1996. Cyclic nucleotide-gated ion channels: an extended family with diverse functions. *Annu. Rev. Physiol.*, **58**: 395–426.
  - 8) Fujii, M., Ide, T., Wadhwa, R., Tahara, H., Kaul, S. C., Mitsui, Y., Ogata, T., Oishi, M. and Ayusawa, D. 1995. Inhibitors of cGMP-dependent protein kinase block senescence induced by inactivation of T antigen in SV40-transformed immortal human fibroblasts. *Oncogene*, **11**: 627–634.
  - 9) Galione, A. 1994. Cyclic ADP-ribose, the ADP-ribosyl cyclase pathway and calcium signaling. *Mol. Cell. Endocrinol.*, **98**: 125–131.
  - 10) Gershengorn, M. C. 1986. Mechanism of thyrotropin releasing hormone, Stimulation of pituitary hormone secretion. *Annu. Rev. Physiol.*, **48**: 515–526.
  - 11) Haby, C., Lisovoski, F., Aunis, D. and Zwiller, J. 1994. Stimulation of the cyclic GMP pathway by NO induces expression of the immediate early genes *c-fos* and *junB* in PC12 cells. *J. Neurochem.*, **62**: 496–501.
  - 12) Huang, J., Zhou, H., Mahavadi, S., Sriwai, W. and Murthy, K. S. 2007. Inhibition of  $G\alpha_q$ -dependent PLC- $\beta$ 1 activity by PKG and PKA is mediated by phosphorylation of GRS4 and GRK2. *Am. J. Physiol. Cell Physiol.*, **292**: C200–C208.
  - 13) Haug, L. S., Jensen, V., Hvalby, Ø., Walaas, S.I. and Østfold, A. C. 1999. Phosphorylation of the inositol 1,4,5-trisphosphate receptor by cyclic nucleotide-dependent kinases in vitro and in rat cerebellar slices in situ. *J. Biol. Chem.*, **274**: 7467–7473.
  - 14) Hsieh, K. P. and Martin, T. F. 1992. Thyrotropin-releasing hormone and gonadotropin-releasing hormone receptors activate phospholipase C by coupling to the guanosine triphosphate-binding proteins Gq and G11. *Mol. Endocrinol.*, **6**: 1673–1681.
  - 15) Komalavilas, P. and Lincoln, T. M. 1996. Phosphorylation of the inositol 1,4,5-trisphosphate receptor. Cyclic GMP-dependent protein kinase mediates cAMP and cGMP dependent phosphorylation in the intact rat aorta. *J. Biol. Chem.*, **271**: 21933–21938.
  - 16) Lee, H. C. 1994. Cyclic ADP-ribose: a new member of a super family of signalling cyclic nucleotides. *Cell. Signal.*, **6**: 591–600.
  - 17) Lincoln, T. M., Dey, N. and Sellak, H. 2001. cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. *J. Appl. Physiol.*, **91**: 1421–1430.
  - 18) Lincoln, T. M., Komalavilas, P. and Cornwell, T. L. 1994. Pleiotropic regulation of vascular smooth muscle tone by cyclic GMP-dependent protein kinase. *Hypertension*, **23**: 1141–1147.
  - 19) Méry, P-F., Lohmann, S. M., Walter, U. and Fischmeister, R. 1991.  $Ca^{2+}$  current is regulated by cGMP-dependent protein kinase in mammalian cardiac myocytes. *Proc. Natl. Acad. Sci. USA*, **88**: 1197–1201.
  - 20) Moncada, S. and Higgs, A. 1993. The L-arginine-nitric oxide pathway. *N. Engl. J. Med.*, **329**: 2002–2012.
  - 21) Moustafa, A., Sakamoto, K. Q. and Habara, Y. 2011. A fundamental role for NO-PLC signaling pathway in mediating intracellular  $Ca^{2+}$  oscillation in pancreatic acini. *Nitric Oxide*, in press.
  - 22) Murad, F. 2008. Nitric oxide and cyclic guanosine monophosphate signaling in the eye. *Can. J. Ophthalmol.*, **43**: 291–294.
  - 23) Nguyen, B. L., Saitoh, M. and Ware, J. A. 1991. Interaction of nitric oxide and cGMP with signal transduction in activated platelets. *Am. J. Physiol.*, **261**: H1043–H1052.
  - 24) Oset-Gasque, M. J., Parramón, M., Hortelano, S., Boscá, L. and González, M. P. 1994. Nitric oxide implication in the control of neurosecretion by chromaffin cells. *J. Neurochem.*, **63**: 1693–1700.
  - 25) Owicki, J. C. 2000. Fluorescence polarization and anisotropy in high throughput screening: Perspectives and primer. *J. Biomol. Screen.*, **5**: 297–306.
  - 26) Publicover, N. G., Hammond, E. M. and Sanders, K. M. 1993. Amplification of nitric oxide signaling by interstitial cells isolated from canine colon. *Proc. Natl. Acad. Sci. U. S. A.*, **90**: 2087–2091.
  - 27) Ramachandran, R., Mihara, K., Mathur, M., Rochdi, M. D., Bouvier, M., DeFea, K. and Hollenberg, M. D. 2009. Agonist-biased signaling via proteinase activated receptor-2: differential activation of calcium and mitogen-activated protein kinase pathways. *Mol. Pharmacol.*, **76**: 791–801.
  - 28) Rooney, T. A., Joseph, S. K., Queen, C. and Thomas, A. P. 1996. Cyclic GMP induces oscillatory calcium signals in rat hepatocytes. *J. Biol. Chem.*, **271**: 19817–19825.
  - 29) Schmidt, H. H. H. W., Lohmann, S. M. and Walter, U. 1993. The nitric oxide and cGMP signal transduction system: regulation and

- mechanism of action. *Biochim. Biophys. Acta*, **1178**: 153–175.
- 30) Stoyanovsky, D., Murphy, T., Anno, P. R., Kim, Y-M. and Salama, G. 1997. Nitric oxide activates skeletal and cardiac ryanodine receptors. *Cell Calcium*, **21**: 19–29.
- 31) Tertyshnikova, S., Yan, X. and Fein, A. 1998. cGMP inhibits IP<sub>3</sub>-induced Ca<sup>2+</sup> release in intact rat megakaryocytes via cGMP- and cAMP-dependent protein kinases. *J. Physiol. (Lond.)*, **512**: 89–96.
- 32) Tritsarlis, K., Looms, D. K., Nauntofte, B. and Dissing, S. 2000. Nitric oxide synthesis causes inositol phosphate production and Ca<sup>2+</sup> release in rat parotid acinar cells. *Pflügers Arch.*, **440**: 223–228.
- 33) Velardez, M. O., Benitez, A. H., Cabilla, J. P., Bodo, C. C. A. and Duvilanski, B. H. 2003. Nitric oxide decreases the production of inositol phosphates stimulated by angiotensin II and thyrotropin-releasing hormone in anterior pituitary cells. *Eur. J. Endocrinol.*, **148**: 89–97.
- 34) Vicente, S., Figueroa, S., Pérez-Rodríguez, R., González, M. P. and Oset-Gasque, M. J. 2005. Nitric oxide donors induce calcium-mobilisation from internal stores but do not stimulate catecholamine secretion by bovine chromaffin cells in resting conditions. *Cell Calcium*, **37**: 163–172.
- 35) Williams, J. A. 2006. Regulation of pancreatic acinar cell function. *Curr. Opin. Gastroenterol.*, **22**: 498–504.
- 36) Willmott, N., Sethi, J. K., Walseth, T. F., Lee, H. C., White, A. M. and Galione, A. 1996. Nitric oxide-induced mobilization of intracellular calcium via the cyclic ADP-ribose signaling pathway. *J. Biol. Chem.*, **271**: 3699–3705.
- 37) Xia, C., Bao, Z., Yue, C., Sanborn, B. M. and Liu, M. 2001. Phosphorylation and regulation of G-protein-activated phospholipase C-β3 by cGMP-dependent protein kinases. *J. Biol. Chem.*, **276**: 19770–19777.